Influenza medical therapy

Revision as of 19:53, 28 May 2013 by Ochuko Ajari (talk | contribs)
Jump to navigation Jump to search

Influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Influenza medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Influenza medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Influenza medical therapy

CDC on Influenza medical therapy

Influenza medical therapy in the news

Blogs on Influenza medical therapy

Directions to Hospitals Treating Influenza

Risk calculators and risk factors for Influenza medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

People with the flu are advised to get plenty of rest, drink a lot of liquids, avoid using alcohol and tobacco and, if necessary, take medications such as paracetamol (acetaminophen) to relieve the fever and muscle aches associated with the flu. Children and teenagers with flu symptoms (particularly fever) should avoid taking aspirin during an influenza infection (especially influenza type B) because doing so can lead to Reye's syndrome, a rare but potentially fatal disease of the liver.[1] Since influenza is caused by a virus, antibiotics have no effect on the infection; unless prescribed for secondary infections such as bacterial pneumonia, they may lead to resistant bacteria. Antiviral medication is sometimes effective, but viruses can develop resistance to the standard antiviral drugs.

The two classes of anti-virals are neuraminidase inhibitors and M2 inhibitors (adamantane derivatives). Neuraminidase inhibitors are currently preferred for flu virus infections. The CDC recommended against using M2 inhibitors during the 2005–06 influenza season.[2]

Neuraminidase inhibitors

Antiviral drugs such as oseltamivir (trade name Tamiflu) and zanamivir (trade name Relenza) are neuraminidase inhibitors that are designed to halt the spread of the virus in the body.[3] These drugs are often effective against both influenza A and B.[4] The Cochrane Collaboration reviewed these drugs and concluded that they reduce symptoms and complications.[5] Different strains of influenza virus have differing degrees of resistance against these antivirals and it is impossible to predict what degree of resistance a future pandemic strain might have.[6]

M2 inhibitors (adamantanes)

The antiviral drugs amantadine and rimantadine are designed to block a viral ion channel and prevent the virus from infecting cells. These drugs are sometimes effective against influenza A if given early in the infection, but are always ineffective against influenza B.[4] Measured resistance to amantadine and rimantadine in American isolates of H3N2 has increased to 91% in 2005.[7]

Antiviral Drugs

These treatments are antiviral drugs that affect the virus itself and may be used as either a prophylactic (that is, before infection) or as treatment. In general, antiviral drugs for treatment of influenza must be taken within a few days of the onset of symptoms.

Due to increasing incidence of drug resistance to amantadine and rimantadine in H3N2 during the 2005-2006 flu season in the United States, the CDC recommended the use of oseltamivir for flu prevention and the use of oseltamivir or zanamivir for flu treatment.[8] [9]

Approved

These prescription drugs have been approved by the US Food and Drug Administration as safe and effective.

Antiviral drugs to treat influenza
Class Effective Against Brand Name Drug Name (INN) Year Approved Manufacturer
M2 inhibitors
(adamantane derivatives)
Influenza A Symmetrel® Amantadine 1976 Endo Pharmaceuticals
Flumadine® Rimantadine 1994 Forest Laboratories
Neuraminidase inhibitors Influenza A & B Relenza® Zanamivir 1999 GlaxoSmithKline
Tamiflu® Oseltamivir 1999 Hoffmann-La Roche
Note: Neuraminidase inhibitors are approved for prophylaxis use in children and adults.

Experimental

Peramivir is being developed by BioCryst Pharmaceuticals, but has not yet been approved for sale in the United States.[10]

Conventional symptomatic relief

Over the counter medicines may be taken to relieve influenza symptoms, but they do not affect the virus.

OTC medicines provide relief for 'flu symptoms[11]
Symptom(s) OTC Medicine
Fever, Aches, Pains, Sinus pressure, Sore throat Analgesics
nasal congestion, sinus pressure Decongestants
sinus pressure, Runny nose, Watery eyes, Cough Antihistamines
cough Cough suppressant
Sore throat local Anesthetics

Children and teenagers with flu symptoms (particularly fever) should avoid taking aspirin as taking aspirin in the presence of influenza infection (especially Influenzavirus B) can lead to Reye's syndrome, a rare but potentially fatal disease of the liver.[12]

Unconventional treatment

Homeopathic and other cold and flu remedies that fail to meet the regulatory requirements as drugs that treat disease, or the standards of evidence-based medicine, are sold as nutritional supplements.

They may be based on extracts of living things, but may lack documentation of their safety and effectiveness.

References

  1. Glasgow, J (2001). "Reye syndrome — insights on causation and prognosis". Arch Dis Child. 85 (5): 351–3. PMID 11668090. Unknown parameter |coauthors= ignored (help)
  2. Centers for Disease Control and Prevention. CDC Recommends against the Use of Amantadine and Rimantadine for the Treatment or Prophylaxis of Influenza in the United States during the 2005–06 Influenza Season. January 14, 2006. Retrieved on 2007-01-01
  3. Moscona, A (2005). "Neuraminidase inhibitors for influenza". N Engl J Med. 353 (13): 1363–73. PMID 16192481.
  4. 4.0 4.1 Stephenson, I (1999). "Chemotherapeutic control of influenza". J Antimicrob Chemother. 44 (1): 6–10. PMID 10459804. Unknown parameter |coauthors= ignored (help)
  5. Jefferson, T. "Neuraminidase inhibitors for preventing and treating influenza in healthy adults". Cochrane Database Syst Rev. 3: CD001265. doi:10.1002/14651858.CD001265.pub2. PMID 16855962. Unknown parameter |coauthors= ignored (help)
  6. Webster, Robert G. (2006). "H5N1 Influenza — Continuing Evolution and Spread". N Engl J Med. 355 (21): 2174–77. PMID 16192481.
  7. "High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents — United States, 2005–06 influenza season". MMWR Morb Mortal Wkly Rep. 55 (2): 44–6. 2006. PMID 16424859.
  8. Smith, Nicole M. (2006-07-28). "Prevention and Control of Influenza". Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. Retrieved 2007-05-25. Unknown parameter |coauthors= ignored (help)
  9. Altman, Lawrence K. (2006-01-15). "This Season's Flu Virus Is Resistant to 2 Standard Drugs". New York Times. Retrieved 2007-05-25.
  10. "Peramivir Fact Sheet" (pdf). BioCryst Pharmaceuticals Inc. Retrieved 2007-05-25.
  11. "Cold and Flu Guidelines: Influenza". American Lung Association. Retrieved 2007-09-16.
  12. Molotsky, Irvin (1986-02-15). "Consumer Saturday - Warning on Flu and Aspirin". New York Times. Retrieved 2007-05-25.

Template:WH Template:WS